

**EMERGING RISK FACTORS AND  
OUTCOME PREDICTORS OF  
CORONARY ARTERY DISEASE IN A  
SRI LANKAN POPULATION**

**BY**

**PORUTHOTAGE PRADEEP RASIKA PERERA**

**Ph. D.**

**2009**

**EMERGING RISK FACTORS AND OUTCOME  
PREDICTORS OF CORONARY ARTERY DISEASE IN A  
SRI LANKAN POPULATION**

**BY**


**PORUTHOTAGE PRADEEP RASIKA PERERA**



Thesis submitted to the University of Sri Jayewardenepura for the  
award of the Degree of Doctor of Philosophy in Biochemistry on  
30<sup>th</sup> January 2009.

### **DECLARATION BY THE CANDIDATE**

The work in this thesis was carried out by me under the supervision of Professor Hemantha Peiris (Head of the Department of Biochemistry, Faculty of Medical Sciences, University of Sri Jayewardenepura), Professor Lal Chandrasena (Professor of Biochemistry, Department of Biochemistry, Faculty of Medicine, University of Kelaniya) and Dr. J. Indrakumar (Senior Lecturer, Department of Medicine, Faculty of Medical Sciences, University of Sri Jayewardenepura) and a report on this has not been submitted in whole or in part to any University or any other institution for another Degree/Diploma.



.....  
Poruthotage Pradeep Rasika Perera

30.01.2009

.....  
Date

## DECLARATION BY THE SUPERVISORS

We certify that the above statement by the candidate is true and that this thesis is suitable for submission to the University for the purpose of evaluation.



.....  
Professor Hemantha Peiris  
(Supervisor)



.....  
Professor L. G. Chandrasena  
(Supervisor)



.....  
Dr. J. Indrakumar  
(Supervisor)

Date: 30<sup>th</sup> January 2009

I dedicate this thesis to  
my parents, my wife Chandana  
and my daughters  
Pavithri, Kaveetha and Dilini.

## TABLE OF CONTENTS

	Page No.
List of Tables	xiv
List of Figures	xvii
List of Plates	xviii
Abbreviations	xix
Acknowledgement	xxii
Abstract	xxv
<b>1. INTRODUCTION</b>	01
<b>1.1 General Introduction</b>	01
<b>1.2 Cardiovascular risk factors</b>	02
1.2.1 Non-modifiable risk factors	02
1.2.1.1 Age	02
1.2.1.2 Gender	02
1.2.1.3 Heredity / family history	03
1.2.1.4 Ethnicity	03
1.2.2 Modifiable risk factors	04
1.2.2.1 Hypertension	04

	Page No.
1.2.2.2 Hypercholesterolaemia and hyperlipidemia	05
i. Elevated total cholesterol	05
ii. Elevated Low-Density Lipoprotein cholesterol (LDL-cholesterol)	05
iii. Low High Density lipoprotein Cholesterol (HDL-cholesterol)	06
1.2.2.3 Effect of tobacco smoking	06
1.2.2.4 Overweight and obesity	07
1.2.2.5 Diabetes mellitus	08
1.2.2.6 Effect of alcohol	08
1.2.2.7 Infrequent exercise/ Physical inactivity	09
<b>1.3 Traditional vs. Novel coronary risk factors</b>	10
<b>1.4 Justification</b>	12
<b>1.5 Objectives</b>	15
1.5.1 General Objectives	15
1.5.2 Specific Objectives	15
<b>2. LITERATURE REVIEW</b>	17
<b>2.1 Homocysteine and CAD</b>	17
2.1.1 Homocysteine metabolism	17
2.1.2 Homocysteine in plasma/Serum	21



	Page No.
2.1.3 Factors affecting plasma (serum)homocysteine levels	24
2.1.3.1 Metabolic derangements affecting plasma (serum) homocysteine levels	24
2.1.3.2 Genetic mutations affecting plasma (serum) homocysteine levels	28
2.1.3.3 Vitamin deficiencies affecting plasma (serum) homocysteine levels	29
2.1.4 Other contributory factors affecting homocysteine levels	30
2.1.5 Homocysteine and its association with coronary artery disease	31
2.1.5.1 Homocysteine as a risk factor for CAD	31
2.1.5.2 Mechanisms responsible for atherosclerosis and CAD in hyperhomocysteinaemia	35
<b>2.2 Apolipoproteins and CAD</b>	39
2.2.1 Apolipoprotein A and apolipoprotein B	39
2.2.2 Apolipoprotein A-I and apolipoprotein B in atherosclerosis and CAD	41
2.2.2.1 Lipids and their role in atherosclerosis	41
2.2.2.2 Assessment of lipid related risk of cardiovascular disease	44
2.2.2.3 Apolipoprotein A-I and apolipoprotein B in the assessment of risk of cardiovascular disease	46
<b>2.3 Glutathione peroxidase and CAD</b>	53
2.3.1 Glutathione peroxidase	53



	Page No.
2.3.2 Glutathione peroxidase in atherosclerosis and CAD	55
<b>2.4 Assessment of severity of coronary ischaemia</b>	59
<b>3. MATERIALS AND METHODS</b>	61
<b>3.1 Chemicals and reagents</b>	61
3.1.1 Water	61
3.1.2 Chemicals	61
3.1.3 Special chemicals/Reagents	61
<b>3.2 Methods</b>	62
3.2.1 Selection of study subjects	62
3.2.1.1 Selection of study subjects for study 1 - Association of Hyperhomocysteinaemia with coronary artery disease in a Sri Lankan population.	62
i. Cases	62
ii. Controls	62
3.2.2 Selection of study subjects for study 2 - Association of Homocysteine, Vitamin B <sub>12</sub> , Folate, Apolipoprotein A-I, Apolipoprotein B, and glutathione peroxidase in CABG patients	63
<b>3.3 Collection of blood samples</b>	63
3.3.1 Study 1:	63
3.3.2 Study 2	64

	Page No.
<b>3.4 Data Collection</b>	65
3.4.1 Study 1	65
3.4.2 Study 2:	67
<b>3.5 Height, weight and Body Mass Index</b>	68
<b>3.6 Method development and analysis of homocysteine concentration by high performance liquid chromatography in study 1</b>	69
3.6.1 Preparation and assay of plasma samples for homocysteine:	69
3.6.2 Apparatus and chromatographic conditions	69
3.6.3 Chromatogram patterns obtained with different mobile phase methanol concentrations	70
3.6.4 Comparison of the internal standards	72
3.6.5 Validation of assay method	72
3.6.6 Performance characteristics of the Homocysteine assay method	74
3.6.7 Calculation of homocysteine concentration	74
3.6.8 Quality control	76
<b>3.7 Quantitative analysis of Vitamin B<sub>12</sub></b>	76
3.7.1 Vitamin B <sub>12</sub> assay procedure	76
3.7.2 Reaction principle	77
3.7.3 Calibration	77
3.7.4 Quality control	78

	Page No.
<b>3.8 Quantitative analysis of folic acid</b>	78
3.8.1 Folic acid assay procedure	78
3.8.2 Reaction principle	79
3.8.3 Calibration	79
3.8.4 Quality control	79
<b>3.9 Quantitative analysis of homocysteine in study 2</b>	80
3.9.1 Homocysteine assay procedure	80
3.9.2 Biological principle of the procedure	81
3.9.3 Calibration	82
3.9.4 Quality control	82
<b>3.10 Quantitative analysis of apolipoprotein A-I</b>	83
3.10.1 Apolipoprotein A-I assay procedure	83
3.10.2 Reaction principle	83
3.10.3 Calibration	83
3.10.4 Quality control	84
<b>3.11 Quantitative analysis of apolipoprotein B</b>	84
3.11.1 Apolipoprotein B assay	84
3.11.2 Reaction principle	84
3.11.3 Calibration	85
3.11.4 Quality control	85

	Page No.
<b>3.12 Quantitative analysis of glutathione peroxidase activity</b>	86
3.12.1 Glutathione peroxidase assay procedure	86
3.12.2 Reaction principle	87
3.12.3 Calibration	87
3.12.4 Quality control	87
<b>3.13 Genotyping to detect MTHFR C677T and A1298C polymorphisms</b>	88
3.13.1 Polymerase chain reaction / restriction fragment length polymorphism	88
3.13.2 DNA extraction	88
3.13.3 Amplification of DNA segments of interest to detect MTHFR C677T and A1298C polymorphisms	90
3.13.3.1 Principle of the PCR procedure	90
3.13.3.2 PCR amplification of DNA for MTHFR C677T polymorphism analysis	91
i. PCR amplification of genomic DNA segment to analyze MTHFR C677T polymorphism using DMD 48 as internal control	91
ii. PCR amplification of genomic DNA segment to analyze MTHFR C677T polymorphism and amplification of bacteriophage $\lambda$ DNA segment to use as internal control.	94
a). PCR amplification of genomic DNA segment to analyze MTHFR C677T:	94

b). Preparation of primers to generate 150bp bacteriophage λ fragment	94
c). PCR amplification of bacteriophage λ DNA segment to use as an internal control	97
3.13.3.3 PCR amplification of DNA for MTHFR A1298C polymorphism analysis	97
3.13.4 Restriction endonuclease digestion of amplified DNA segments to detect MTHFR C677T and A1298C polymorphisms	100
3.13.4.1 Restriction endonuclease digestion of amplified DNA segments with <i>Hinf</i> I to detect MTHFR C677T polymorphism	100
i). Restriction endonuclease digestion of amplified DNA segments with <i>Hinf</i> I to detect MTHFR C677T polymorphism using DMD as internal control	101
ii. Restriction endonuclease digestion of amplified DNA segments with <i>Hinf</i> I to detect MTHFR C677T polymorphism using bacteriophage λ 150bp PCR product as internal control.	101
3.13.4.2 Restriction endonuclease digestion of amplified DNA segments with <i>Mbo</i> II to detect MTHFR A1298C polymorphism	102



	Page No.
3.13.5 Visualization of DNA fragments with agarose gel electrophoresis	103
3.13.5.1 Preparation of the agarose gel	103
3.13.5.2 Electrophoresis of prepared DNA samples using the prepared agarose gels.	104
3.13.6 Quality control	105
<b>3.14 Calculation of severity of ischaemia in study 2</b>	106
3.14.1 Calculation of vessel score	106
3.14.2 Calculation of stenosis score	106
3.14.3 Calculation of extent score	107
<b>3.15 Data processing and analysis</b>	108
<b>3.16 Ethical considerations</b>	108
 <b>4. RESULTS</b>	109
<b>4.1 Study I</b>	109
4.1.1 Characteristics of study subjects	109
4.1.2 Association between Hyperhomocysteinaemia and CAD	116
4.1.3 Association between hyperhomocysteinaemia and CAD in the young and adults over 50 years of age	118
4.1.4 Association of risk of CAD in persons with two or less traditional risk factors for the development of CAD and with patients with 3 or more traditional risk factors	120

	Page No.
<b>4.2 Study II</b>	123
4.2.1 Characteristics of study subjects	123
4.2.1.1 General characteristics of the study subjects	123
4.2.1.2 Biochemical and anthropometric characteristics of the study population.	123
4.2.2 Association of vitamin B <sub>12</sub> and folate with Homocysteine concentrations in patients with coronary artery Disease.	129
4.2.3 MTHFR C677T/A1298C polymorphism analysis:	131
4.2.3.1 Comparison of the internal controls and results of agarose gel electrophoresis in MTHFR C677T polymorphism analysis	131
4.2.3.2 MTHFR A1298C polymorphism analysis using agarose gel electrophoresis	134
4.2.4 Association between Hyperhomocysteinaemia and MTHFR gene polymorphisms (A1298C, C677T polymorphism):	134
4.2.5 Severity of coronary artery disease in the study population	140
4.2.6 Association between vitamin B <sub>12</sub> , Folate, and Homocysteine concentrations with the severity of coronary artery disease.	140
4.2.7 Association of Apolipoprotein A-I, Apolipoprotein B and Glutathione peroxidase with the severity of coronary artery disease	142
4.2.8 Association of age with Apolipoprotein A-I, Apolipoprotein B, glutathione peroxidase concentrations in coronary artery disease patients	144



	Page No.
<b>5. DISCUSSION</b>	146
<b>5.1 Association between Hyperhomocysteinaemia and CAD</b>	146
5.1.1 High performance liquid chromatography in the assay of Homocysteine	146
5.1.2 Association between Hyperhomocysteinaemia and coronary artery disease	150
<b>5.2 Association between hyperhomocysteinaemia and CAD in the young (age ≤ 50 years) compared to the elderly (age &gt; 50 years).</b>	157
<b>5.3 Association between Hyperhomocysteinaemia and the number of risk factors (having two or less traditional risk factors compared to 3 or more traditional risk factors) among coronary artery disease patients.</b>	161
<b>5.4 Deficiency vitamin/s (vitamin B<sub>12</sub> and folate) giving rise to hyperhomocysteinaemia in patients with coronary artery disease.</b>	163
<b>5.5 Association between Hyperhomocysteinaemia and MTHFR gene mutations (A1298C, C677T polymorphism) using restriction fragment length polymorphism analysis</b>	168
5.5.1 Use of bacteriophage λ DNA as an internal control in restriction enzyme digestion in the MTHFR C677T gene mutation analysis by RFLP agarose gel electrophoresis	168
5.5.2 Prevalence of MTHFR C677T polymorphism in the study sample	172
5.5.3 Prevalence of MTHFR A1298C polymorphism in the study sample	173

	Page No.
5.5.4 Association of MTHFR C677T gene mutations (A1298C, C677T polymorphisms) with homocysteine concentrations in CAD patients in the study sample.	174
<b>5.6 Association between, vitamin B<sub>12</sub>, Folate, and Homocysteine levels with the severity of coronary artery disease.</b>	177
<b>5.7 Association of Apolipoprotein A-I, Apolipoprotein B and Glutathione peroxidase with severity of coronary artery disease.</b>	181
<b>5.8 Influence of age on the association of apolipoprotein A-I, apolipoprotein B and glutathione peroxidase concentrations with coronary artery disease patients.</b>	186
<b>6. CONCLUSIONS</b>	189
<b>7. REFERENCES</b>	193
<b>8. APPENDICES</b>	
Appendix 1: List of Publications and Communications from Thesis	259
Appendix 2: Questionnaire used in study 1	261
Appendix 3: Questionnaire/Data sheet used in study 2	263
Appendix 4: Ethical clearance for study 1	265
Appendix 5: Ethical clearance for study 2 (excluding genetic analysis)	266
Appendix 6: Ethical clearance for the genetic analysis in study 2	267
Appendix 7: Information leaflet used in study 1(English)	268
Appendix 8: Information leaflet used in study 1(Sinhala)	269

	Page No.
Appendix 9: Research consent form used in study 1- (English)	270
Appendix 10: Research consent form used in study 1- (Sinhala)	271
Appendix 11: Research consent form used in study 2	272

## List of Tables

	Page No:
Table 3.1      Comparison of retention times for homocysteine and internal standard (cystamine dihydrochloride) after 3 months storage at -20 °C.	75
Table 3.2      PCR primers used for the PCR/RFLP genotyping assays to genotype the MTHFR C677T polymorphism and the initial internal control DMD 48.	93
Table 3.3      PCR primers developed for amplification of selected bacteriophage $\lambda$ 154 bp segment.	96
Table 3.4.      PCR primers used for the PCR/RFLP genotyping assays to genotype the <i>MTHFR</i> A1298C polymorphism.	99
Table 4.1      Prevalence characteristics of the subjects in study 1.	111
Table 4.2      Weight, height and BMI of cases and controls in study 1.	112
Table 4.3      Homocysteine concentrations of the subjects in the study.	112
Table 4.4      Correlation between plasma homocysteine concentration and age in the study population.	115
Table 4.5      Conditional logistic regression analysis of confounding variables.	117
Table 4.6      Association between hyperhomocysteinaemia and CAD by age group.	119

		Page No:
Table 4.7	Frequency distribution of number of traditional risk factors in CAD patients and controls	121
Table 4.8	Association between the number of traditional risk factors and development of CAD.	122
Table 4.9	Association between homocysteine levels and number of traditional risk factors in CAD patients.	122
Table 4.10	Personal characteristics of subjects in study 2.	124
Table 4.11	Biochemical and anthropometric characteristics of subjects in study 2.	127
Table 4.12	Association of vitamin B <sub>12</sub> and folate concentrations to Homocysteine concentrations.	130
Table 4.13	Significance of the association between vitamin B <sub>12</sub> and folate with normal homocysteine levels and hyperhomocysteinaemia at different cut off values.	130
Table 4.14	Genotype frequencies for MTHFR A1298C and C677T polymorphisms of the study sample (n=79).	135
Table 4.15	Relationship between MTHFR C677T genotype and homocysteine, folate and vitamin B <sub>12</sub> concentrations.	137
Table 4.16	Relationship between A1298C genotype and homocysteine, folate and vitamin B <sub>12</sub> concentrations.	138



Table 4.17	Relationship between MTHFR A1298C /C677T genotype combinations and homocysteine concentrations.	139
Table 4.18	Severity of ischaemia in the study sample.	141
Table 4.19	Association of vitamin B <sub>12</sub> , Folate, and Homocysteine concentrations to severity of CAD.	141
Table 4.20	Association of apolipoprotein A-I, apolipoprotein B and glutathione peroxidase to severity of CAD.	143
Table 4.21	Influence of age on the association of apolipoprotein A-I, apolipoprotein B, glutathione peroxidase on coronary artery disease.	145

## LIST OF FIGURES

		Page No:
Figure 2.1	Schematic diagram of the Homocysteine metabolic pathway in humans.	20
Figure 2.2	Structure of Homocysteine and its oxidized forms in plasma.	23
Figure 3.1	Chromatogram of a representative plasma sample measured at a methanol concentration of 30 ml/L.	71
Figure 3.2	Chromatogram of a representative plasma sample measured at a methanol concentration of 12 ml/L.	71
Figure 3.3	Chromatogram of Homocysteine standard (70 $\mu\text{mol/L}$ ) and Internal standard Mercapto-propionyl-glycine (200 $\mu\text{mol/L}$ ).	73
Figure 3.4	Chromatogram of Homocysteine standard (70 $\mu\text{mol/L}$ ) and internal standard Cystamine dihydrochloride (200 $\mu\text{mol/L}$ ).	73
Figure 3.5	Homocysteine standard curve.	75
Figure 4.1	Distribution of serum homocysteine with age in normal subjects of study 1.	114
Figure 4.2	Distribution of serum homocysteine with age in CAD patients of study 1.	114
Figure 4.3	Distribution of serum homocysteine with age in CAD patients of study 2.	128



## LIST OF PLATES

	Page No:
Plate 4.1	MTHFR 677C>T genotyping: The pattern created by electrophoresing the Hinf I digested PCR products of samples of the three genotypes and the DMD 48 internal control on a 2% agarose gel. 132
Plate 4.2	MTHFR 677C>T genotyping: The pattern created by electrophoresing the Hinf I digested PCR products of samples of the three genotypes and the 150bp bacteriophage $\lambda$ DNA internal control on a 2% agarose gel. 133
Plate 4.3	MTHFR A1298C genotyping: The pattern created by electrophoresing the Mbo II digested PCR products of samples of the three genotypes on a 2% agarose gel. 135

## ABBREVIATIONS

Apo-A	Apolipoprotein A
Apo B	Apolipoprotein B
BMI	Body Mass Index
CABG	Coronary artery bypasses grafting
CAD	Coronary Artery Disease
CHD	Coronary Heart Disease
CPK	Creatine phospho kinase
CV	Coefficient of variation
CVD	Coronary Vascular Disease
dATP	deoxy Adenosine Triphosphate
dCTP	deoxy Cytosine Triphosphate
dGTP	deoxy Guanosine Triphosphate
DMD	Duchene's Muscular Dystrophy
DNA	Deoxy ribonucleic acid
dTTP	deoxy Thymidine Triphosphate
EDTA	Ethylenediaminetetraacetic acid
FPIA	Fluorescence Polarization Immunoassay
GNMT	Glycine N-methyltransferase
GPX	Glutathione Peroxidase 1
Hb	Haemoglobin
HDL	High-density lipoprotein cholesterol
HPLC	High Performance Liquid Chromatography
ICD	International Classification of Diseases

IDL	Intermediate-density lipoprotein
IHD	Ischaemic Heart Disease
LCAT	Lecithin cholesterol acyl transferase
LDL	Low-density lipoprotein
Lp(a)	Lipoprotein (a)
MI	Myocardial infarction
MTHFR	Methylenetetrahydrofolate reductase
n	Number
NEB	New England Biolabs
OR	Odds ratio
PAR	Population attributable risks
PBS	Phosphate buffered saline
PCR	Polymerase Chain Reaction
PLP	Pyridoxal-5'-phosphate
RBC	Red blood cell
RFLP	Restriction Fragment Length Polymorphism
RNase	Ribonuclease
ROS	Reactive Oxygen Species
RP-HPLC	Reversed phase HPLC
RV	Reaction vessel
SAH	S-adenosylhomocysteine
SAM	S-adenosyl methionine
SD	Standard deviation
sd LDL	Small dense LDL

TAE	Tris acetate EDTA
TBP	Tri-butyl phosphine
TC	Total cholesterol
TCEP	<i>Tris</i> (2-carboxyethyl)phosphine
TG	Triglyceride
SBD-F	7-Fluorobenzofurazan-4-sulfonic acid Ammonium salt
U.K.	United Kingdom
U.S.A.	United States of America
UV	ultra violet
VLDL-C	Very Low-density lipoprotein cholesterol
WHO	World Heath Organization

## ACKNOWLEDGEMENT

I wish to thank all those who contributed in different ways to the work involved in this thesis.

In particular, I would like to express my heartfelt gratitude to:-

My supervisor, Professor Hemantha Peiris ( Head, Department of Biochemistry, Faculty of Medical Sciences, University of Sri Jayewardenepura) for many individual acts of kindness, guidance, support and encouragement, too numerous to mention here, given to me throughout the research project as well as in preparation of this manuscript. This work would not have been feasible without his help.

My supervisor, Prof. L. G. Chandrasena (Professor of Biochemistry, Faculty of Medicine, University of Kelaniya) for his invaluable guidance throughout the research project and in preparation of this manuscript and especially for granting permission to carry out the second part of my study at Nawaloka Hospitals PLC, Colombo 2, Sri Lanka.

My supervisor, Dr. J. Indrakumar, (Senior Lecturer, Department of Medicine, Faculty of Medical Sciences, University of Sri Jayewardenepura) for his invaluable guidance and encouragement throughout the research project as well as in preparation of this manuscript.

Prof. Rajitha Wickremasinghe (Dean, Faculty of Medicine, University of Kelaniya) for the invaluable guidance extended to me regarding statistics during the course of this study as well as helping me in the statistical analysis of this project.

Dr. Upeksha Samaraweeraarachchi for the help extended to me in recruitment of subjects and collection of blood samples from Colombo South Teaching Hospital, Kalubowila in study 1.



Dr. Hemant D. Waikar, Consultant Cardiothoracic Anesthetist, Nawaloka Hospitals (Pvt.) Ltd, Colombo for help extended to me in recruitment of subjects, filling the questionnaire and help in getting the coronary angiography readings in study 2.

Nawaloka Hospitals PLC Colombo and Nawaloka Metropolis Laboratories for giving me the opportunity to utilize the facilities available at the pathology laboratory and Mr. Anton Fernando and the staff of the pathology laboratory for training me in the operation of laboratory instruments.

Consultant Cardiothoracic Surgeons of Nawaloka Hospitals PLC for assistance given in reading the angiograms.

Dr. Neil Fernandopulle the Head of GENETECH Private Ltd. Colombo 8, for his excellent supervision and training given to me in carrying out the genetic analyses and especially for giving me the opportunity to utilize the facilities available at their institution.

Dr. Shamini Prathapan, (Lecturer, Dept. of Community Medicine, Faculty of Medical Sciences, University of Sri Jayewardenepura) for helping me with some of the statistical analyses in the second part of this study.

All subjects for volunteering to take part in this study, without whom this study would have been impossible.

My colleagues at the Department of Biochemistry for their support and encouragement as well as in providing their technical knowhow at times of need.

University of Sri Jayewardenepura for research grants ASP/6/R/2002/1, ASP/6/R/2005/12 and ASP/6/2007/4 and the National Science Foundation for the scholarship NSF/SCH/2007/1 which helped me in covering part of the cost of the study.

My parents and my wife for the support and encouragement extended to me throughout the study and my daughters for their tolerance, patience and for providing the much needed relaxation during difficult times.



# **Emerging risk factors and outcome predictors of coronary artery disease (CAD) in a Sri Lankan population**

**PORUTHOTAGE PRADEEP RASIKA PERERA**

## **ABSTRACT**

**Introduction:** Coronary Artery Disease (CAD) is the number one killer disease in Sri Lanka. Apart from the conventional risk factors for CAD, a few new risk factors have been identified. Of these fasting hyperhomocysteinaemia (HHcy), elevated apolipoprotein B, decreased apolipoprotein A-I and the deficiency of the cardiovascular associated antioxidant Glutathione Peroxidase (GPx) have been reported to be significantly associated with CAD.

**Objectives:** This study was designed to determine a). the association between HHcy and CAD and whether this association was age dependent; b). the likely causes of variations in homocystien levels [mainly changes in serum vitamin B<sub>12</sub> and folate status, and methylenetetrahydrofolate reductase (MTHFR) A1298C and C677T gene polymorphisms], and c). the association of novel risk factors such as folate, vitamin B<sub>12</sub>, apolipoprotein A-1, apolipoprotein B, GPx and HHcy in relation to severity of Coronary Artery Disease (CAD).

**Methods:** A case control study was conducted using 221 subjects with diagnosed acute coronary syndromes and 221 age and sex matched controls to assess the association between HHcy and CAD. The associations between severity of CAD and the other risk factors and folate and vitamin B<sub>12</sub> with homocysteine were also assessed in 79 subjects with diagnosed CAD.

**Results:** Results revealed that there was a significant association ( $p = 0.002$ ) between HHcy and CAD. Furthermore, a significant association ( $p=0.02$ ) was observed between

HHcy and CAD in young patients but not in subjects over 50 years of age. HHcy was found to be a significant predictor of CAD after controlling for hypertension and hypercholesterolaemia (adjusted odds ratio 2.411). The vitamin B<sub>12</sub> and folate levels showed a significantly ( $p < 0.01$ ) negative correlation with serum homocysteine concentrations. There was no significant association ( $p > 0.05$ ) between MTHFR C677T and A1298C polymorphisms and homocysteine levels.

Serum homocysteine and folate levels were not significantly related to the severity of coronary artery disease. However, the serum vitamin B<sub>12</sub> concentrations showed a significant negative correlation with severity of ischaemia when assessed by the vessel score ( $p < 0.05$ ) and the extent score ( $p < 0.01$ ). Apolipoprotein A-1 (inversely) and apolipoprotein B/A-1 ratio showed a significant correlation ( $p < 0.01$ ) with the stenosis and extent scores but not with the vessel score whilst the apolipoprotein B levels correlated significantly only with the vessel score ( $p < 0.05$ ). GPx showed a significant inverse correlation ( $p < 0.001$ ) with the vessel, the stenosis and the extent scores. This has not been reported in the literature before.

Conclusions: Hyperhomocysteinaemia is an independent risk factor for CAD and its association is more in the young compared to elderly subjects. While MTHFR gene polymorphisms were not associated with homocysteine concentrations, a decrease in serum concentrations of either vitamin B<sub>12</sub> or folate was associated with higher homocysteine concentrations. GPx, Apolipoprotein B/A-1 ratio and Apolipoprotein A-1 are better predictors of severity of CAD than apolipoprotein B and homocysteine and they may have a value in assessing the severity of CAD in the future.